Dr Louise Fearfield

Consultant Dermatologist MA DM FRCP

Specialism: Skin

Available at: Chelsea

Special interests:

  • skin cancer
  • general dermatology

Biography

Dr Louise Fearfield has both a private and an NHS practice at The Royal Marsden. She is a Consultant Dermatologist with an interest in skin cancer and cutaneous oncology at The Royal Marsden and Chelsea and Westminster Hospitals.

She did her medical training at Oriel College Oxford and St Thomas’ Hospital London, qualifying as a doctor in 1992. Her first dermatology training post was at Chelsea and Westminster Hospital and The Royal Marsden, which she started in 1995. During this time she developed her interest in skin cancer and took two years out to complete her DM thesis on prognostic factors in melanoma, which was awarded in 2002 at Oxford University. 

She was initially appointed as a Consultant Dermatologist at the Royal Berkshire Hospital and Honorary Consultant at The Royal Marsden in 2002, leaving in 2010. During this time she set up the local skin cancer service, chaired the skin cancer multidisciplinary clinic and recruited the first skin cancer nurse specialist for the region. In 2009 she successfully completed the first peer review for skin cancer for the network and local region.

For the last two years she has also been chair of the Thames Valley Cancer Network for skin cancer, involved in strategic planning for skin cancer and development of services and guidelines for treatment. She was also appointed Chair of the Skin Cancer Thames Valley Tumour Network Group in 2008 until she left in 2010.

Her present appointment is to develop the rapid diagnostic service for primary skin cancer in The Royal Marsden’s Rapid Diagnostic and Assessment Centre, and to run the primary skin cancer service and chair the local multidisciplinary team meeting at the Chelsea and Westminster.

Her research interests remain with prognostic factors in primary melanoma. However, since her appointment to The Royal Marsden she has also developed a research interest in the cutaneous toxicities associated with the newer targeted therapies used in the treatment of metastatic malignant melanoma. She has published several articles recently on this work and has been an invited speaker at national and international meetings.

Clinical units